{"product_id":"bnr-bcg-matrix","title":"(BNR) Burning Rock Biotech Limited BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Burning Rock Biotech Limited BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-Hospital Business, China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited's In-Hospital Business in China is its main scale-up channel, because it fits the faster adoption of NGS-based oncology testing inside hospitals. As hospital penetration rises, this is the clearest Star candidate in the BCG matrix, with repeat testing helping build clinician stickiness and long-term test reuse. In China, the addressable hospital base is still large, so even modest penetration gains can lift volume fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncoScreen IO, tissue pan-cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncoScreen IO is Burning Rock Biotech Limited’s broad tissue pan-cancer assay, so it has clinical reach across many solid tumors and fits the fast-growing precision-oncology market. In hospital workflows, wider use can lift test volume and move it toward a dominant position. As one of Burning Rock Biotech Limited’s flagship tests, it is a key Star in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncoCompass IO, liquid biopsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncoCompass IO fits Burning Rock Biotech Limited's Star bucket if usage keeps rising: liquid biopsy is less invasive than tissue sampling, and oncology adoption keeps widening. China had about 4.82 million new cancer cases in 2022, so precision-medicine testing has a huge base to tap. If this test keeps winning routine use, it can scale fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncoCompass Target, NSCLC ctDNA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncoCompass Target for NSCLC ctDNA sits in a star lane: China had about 1.06 million new lung cancer cases in 2022, and ctDNA fits the shift to minimally invasive monitoring. That gives Burning Rock Biotech Limited a large, high-growth pool if adoption keeps rising.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge NSCLC base in China\u003c\/li\u003e\n\u003cli\u003ectDNA supports repeated monitoring\u003c\/li\u003e\n\u003cli\u003eHigh growth if adoption stays strong\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharma Research and Development Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharma Research and Development Services is the clearest Star-like engine in Burning Rock Biotech Limited’s BCG mix. It has 8 named partners, including AstraZeneca, Bayer, Johnson \u0026amp; Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA, which supports repeat external demand as oncology pipelines grow.\u003c\/p\u003e\n\u003cp\u003eClinical and biomarker work can scale with each new study, so revenue can rise even when project margins shift. The unit’s value is not just one contract; it is the ability to keep winning work across large drug makers and pipeline-heavy biotech clients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8 major pharma and biotech partners\u003c\/li\u003e\n\u003cli\u003eScales with oncology pipeline growth\u003c\/li\u003e\n\u003cli\u003eExternal demand stays active\u003c\/li\u003e\n\u003cli\u003eMargins vary by project\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s Oncology Stars Tap China’s Huge Cancer Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s Stars are In-Hospital Business in China, OncoScreen IO, OncoCompass IO, OncoCompass Target for NSCLC ctDNA, and Pharma Research and Development Services. They sit in high-growth oncology niches with scale upside from China’s 4.82 million new cancer cases and 1.06 million lung cancer cases in 2022, plus 8 pharma partners.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn-Hospital Business\u003c\/td\u003e\n\u003ctd\u003eLarge China hospital base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncoScreen IO\u003c\/td\u003e\n\u003ctd\u003eBroad pan-cancer reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e8 named partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBurning Rock Biotech’s BCG Matrix highlights which businesses to invest in, hold, or divest across all four quadrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG matrix highlighting Burning Rock Biotech Limited’s portfolio pain points and priorities for quick executive review\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBurning Rock Biotech Limited’s reference sources provide a credible audit trail that supports faster, more confident decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentral Laboratory Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s Central Laboratory Business is one of its three operating segments and the most established service model, unlike newer hospital penetration efforts. Its mature workflows and repeat testing support steadier revenue and lower operating friction, which is why it fits the Cash Cow profile in the BCG Matrix. In 2025 filings, the segment remained the likeliest internal cash generator for the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eColonCore, GI testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited's ColonCore GI testing targets colorectal and broader gastrointestinal mutations plus MSI, so it sits in a mature diagnostic niche with recurring clinical use. That makes it a Cash Cow candidate if sample volume stays steady, because GI diagnostics are established rather than early-stage. Stable demand matters more here than fast growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncoScreen ParpMatch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncoScreen ParpMatch is an HRD-linked test, so it sits in a defined oncology pathway where repeat use is tied to treatment choice and follow-up. HRD is present in about 50% of ovarian cancers and 20% to 30% of breast cancers, which keeps demand steady but narrower than lung or broad pan-cancer testing. That profile fits a mature, cash-generating niche for Burning Rock Biotech Limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncoCompass ParpMatch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncoCompass ParpMatch is a niche PARP\/HRD assay, so it fits a Cash Cow better than a Star in Burning Rock Biotech Limited’s BCG Matrix. Once treatment centers adopt a specialized test, switching costs and routine use can keep demand steady even if growth is slower than broad oncology panels. A stable, clinic-embedded workflow is the key cash engine here.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized PARP\/HRD use case\u003c\/li\u003e\n\u003cli\u003eLower growth, steadier demand\u003c\/li\u003e\n\u003cli\u003eAdoption can support repeat testing\u003c\/li\u003e\n\u003cli\u003eCash Cow profile, not a Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEstablished lung and GI NGS workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s lung and gastrointestinal NGS workflows fit Cash Cow status because they are already part of routine oncology care, especially in high-volume cancers where repeat testing supports treatment choice and monitoring. In its latest disclosed reporting cycle, the Company kept these core workflows as the main revenue base, with lower go-to-market spend than newer assays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume lung and GI testing\u003c\/li\u003e\n\u003cli\u003eEmbedded in oncology decision-making\u003c\/li\u003e\n\u003cli\u003eRecurring service revenue profile\u003c\/li\u003e\n\u003cli\u003eLower promo spend than growth tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat mix usually means steadier gross profit and less sales friction, which is classic Cash Cow behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s Steady Oncology Cash Cows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s Cash Cow set is its mature, repeat-use oncology tests: Central Laboratory Business, GI panels, and PARP\/HRD assays. These niches have steadier demand than newer assays; HRD is seen in about 50% of ovarian cancers and 20% to 30% of breast cancers, supporting recurring clinical use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHRD in ovarian cancer\u003c\/td\u003e\n\u003ctd\u003eAbout 50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHRD in breast cancer\u003c\/td\u003e\n\u003ctd\u003e20% to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eBurning Rock Biotech Limited Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Burning Rock Biotech Limited BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages, no hidden changes—just the full, ready-to-use report. Once purchased, the complete file is instantly available for download and use. What you preview is exactly what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLymphoma testing portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited's lymphoma testing portfolio is narrower than its lung or GI testing lines, so the addressable clinical volume is smaller and growth can lag. That usually means weaker scale economics and less pricing power, which fits a Dog profile in BCG terms. Lymphoma is more of a niche support test than a core 2025\/2026 growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThyroid testing portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThyroid testing sits inside Burning Rock Biotech Limited’s broader coverage list, but it is likely a low-volume service versus the flagship lung, pan-cancer, and MRD lines. With limited scale and weaker contribution to testing mix, it fits the Dog quadrant in a BCG Matrix. In BCG terms, a Dog is a low-share, low-growth business that ties up resources without clear growth upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOvarian testing portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOvarian testing sits in Burning Rock Biotech Limited’s coverage, but it is a niche pool versus lung cancer. Ovarian cancer had about 324,000 new cases and 207,000 deaths worldwide in 2022, yet screening demand stays limited, so test volume and revenue share are likely small. That profile fits Dog status: low share, modest growth, and little chance to anchor the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePancreatic testing portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited's pancreatic testing portfolio fits the Dog box because pancreatic cancer is a small, hard-to-screen market: it is about 3% of new cancer cases in the United States, but it drives about 8% of cancer deaths. That mix supports clinical need, yet routine test volume stays well below lung, breast, and colorectal panels, so growth and share are limited.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall addressable market\u003c\/li\u003e\n\u003cli\u003eLow repeat testing volume\u003c\/li\u003e\n\u003cli\u003eWeak scale economics\u003c\/li\u003e\n\u003cli\u003eHard to justify heavy capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Burning Rock Biotech Limited, that means the portfolio can stay clinically useful, but it is unlikely to be a major profit pool unless adoption jumps sharply or reimbursement widens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBladder testing portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBladder testing fits Burning Rock Biotech Limited’s cancer coverage set, but it sits in a narrower market than flagship oncology panels. Bladder cancer remains a valid diagnostic area, yet its smaller addressable pool and lower revenue scale usually limit growth and share gains, which is why this portfolio is most consistent with a Dog in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValid diagnostic line, but niche demand.\u003c\/li\u003e\n\u003cli\u003eSmaller market caps growth potential.\u003c\/li\u003e\n\u003cli\u003eLower scale weakens BCG rank.\u003c\/li\u003e\n\u003cli\u003eBest fit: Dog.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBurning Rock’s Niche Cancer Tests Look Like Dogs, Not Growth Drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited’s lymphoma, thyroid, ovarian, pancreatic, and bladder tests look like Dogs: niche demand, low volume, and weak scale. Ovarian cancer had 324,000 new cases and 207,000 deaths worldwide in 2022, while pancreatic cancer is about 3% of U.S. new cases but 8% of deaths. These lines can stay useful, but they are not core growth engines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOvarian\u003c\/td\u003e\n\u003ctd\u003eNiche\u003c\/td\u003e\n\u003ctd\u003e324k cases, 207k deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic\u003c\/td\u003e\n\u003ctd\u003eLow scale\u003c\/td\u003e\n\u003ctd\u003e3% cases, 8% deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad myChoice tumor testing, China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited has a development and commercialization license for Myriad myChoice tumor testing in China, which gives it a real entry point in HRD testing. HRD use can expand as precision oncology grows and PARP-linked treatment selection rises, but China share is still early-stage, so the product remains a Question Mark. The upside is clear, but the win rate still depends on adoption, reimbursement, and clinical proof.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDetermaRx, China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited licensed DetermaRx from Oncocyte for China, and the test fits a large need: GLOBOCAN 2022 estimates about 1.06 million new lung cancer cases in China. It targets early-stage lung cancer risk stratification, so the use case is clinically relevant and adoption can build if hospitals see clear utility. But its share base is still not proven, which keeps DetermaRx in Question Mark territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHRD companion diagnostics, China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHRD companion diagnostics in China are tied to PARP inhibitor selection, and demand is still rising as more ovarian and breast cancer patients are tested. The NMPA has already cleared 3 PARP inhibitors, but HRD testing standards and payer coverage are still uneven. Burning Rock Biotech Limited has a product set here, yet it has not built clear market leadership across China. That makes this a Question Mark: growth is real, but share is still being won.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEarly-stage NSCLC risk stratification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly-stage NSCLC risk stratification around DetermaRx sits in Burning Rock Biotech Limited's Question Mark bucket: NSCLC is about 85% of lung cancers, so the care-pathway pool is large, but the test's share is still hard to pin down.\u003c\/p\u003e\n\u003cp\u003eIf adoption rises in post-surgery decision making, the addressable market can widen fast, but current penetration and reimbursement traction remain uncertain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge unmet need in early NSCLC\u003c\/li\u003e\n\u003cli\u003eMarket can expand with adoption\u003c\/li\u003e\n\u003cli\u003eCurrent share is still unclear\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led new assay pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited has 8 partner-led assay tracks with AstraZeneca, Bayer, Johnson \u0026amp; Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA, which can seed new diagnostics. These programs sit in a growing precision-oncology market, but each still needs clinical uptake, reimbursement, and scale, so revenue is not yet proven. That mix of high upside and low market share makes them Question Marks in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8 partner programs\u003c\/li\u003e\n\u003cli\u003eHigh growth, low proof\u003c\/li\u003e\n\u003cli\u003eAdoption still the key hurdle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-upside oncology bets, but adoption is still the hurdle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBurning Rock Biotech Limited's Question Marks are still early-share bets: Myriad myChoice, DetermaRx, and other partner assays target large China oncology pools, but adoption, reimbursement, and clinical proof are not yet secure. That keeps upside high and market share low, so growth is real but not yet converted into durable revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyriad myChoice\u003c\/td\u003e\n\u003ctd\u003eHRD growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetermaRx\u003c\/td\u003e\n\u003ctd\u003eNSCLC demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8 partner assays\u003c\/td\u003e\n\u003ctd\u003ePipeline upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234147442953,"sku":"bnr-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bnr-bcg-matrix.webp?v=1785713394","url":"https:\/\/dcfanalyst.com\/products\/bnr-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}